+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Allergic Rhinitis Pipeline Analysis and Outlook, 2019

  • ID: 4772502
  • Report
  • 119 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AFFiRiS AG
  • Archivel Farma SL
  • Daewon Pharm Co Ltd
  • Fountain Biopharma Inc
  • Hanlim Pharm Co Ltd
  • Laboratorios LETI SL
  • MORE
Allergic Rhinitis pipeline

Allergic Rhinitis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Allergic Rhinitis R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Allergic Rhinitis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Allergic Rhinitis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Allergic Rhinitis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Allergic Rhinitis pipeline Profiled in detail

Key players actively participating in Allergic Rhinitis pipeline are profiled along with their R&D progress in Allergic Rhinitis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Allergic Rhinitis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Allergic Rhinitis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Allergic Rhinitis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Allergic Rhinitis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Allergic Rhinitis pipeline study
  • All recent news and developments related to Allergic Rhinitis drugs are provided
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AFFiRiS AG
  • Archivel Farma SL
  • Daewon Pharm Co Ltd
  • Fountain Biopharma Inc
  • Hanlim Pharm Co Ltd
  • Laboratorios LETI SL
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Allergic Rhinitis Disease Overview

3. Allergic Rhinitis Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Allergic Rhinitis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Allergic Rhinitis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Allergic Rhinitis companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Allergic Rhinitis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Accolade Pharmaceuticals LLC
  • AFFiRiS AG
  • ALK-Abello AS
  • AOBiome LLC
  • Archivel Farma SL
  • ASIT Biotech SA
  • CKD Pharma
  • CSPC Pharmaceutical Group Limited
  • Daewon Pharm Co Ltd
  • Dobecure SL
  • Emergo Therapeutics
  • Fountain Biopharma Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • HAL Allergy BV
  • Hanlim Pharm Co Ltd
  • Inmunotek SL
  • Intrommune Therapeutics
  • Laboratorios LETI SL
  • Marinomed Biotech AG
  • Mitsubishi Tanabe Pharma Corp
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Sedor Pharmaceuticals LLC
  • Seelos Therapeutics Inc
  • Stallergenes Greer plc
  • Vactech Oy
  • Xencor Inc
Note: Product cover images may vary from those shown
Adroll
adroll